A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma

Human Gene Therapy

Volumn 26, Issue 9, 2015, Pages 635-646

  Kim, Julius W ^a   Kane, J Robert ^a   Young, Jacob S ^a   Chang, Alan L ^a   Kanojia, Deepak ^a   Morshed, Ramin A ^a   Miska, Jason ^a   Ahmed, Atique U ^a   Balyasnikova, Irina V ^a   Han, Yu ^a   Zhang, Lingjiao ^a   Curiel, David T ^b   Lesniak, MacIej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHIMERIC PROTEIN; FIBRITIN; PEPTIDE; PHAGE PANNED PEPTIDE; SURVIVIN; UNCLASSIFIED DRUG; FIBRITIN PROTEIN, ENTEROBACTERIA PHAGE T4; ONCOLYTIC VIRUS; PEPTIDE LIBRARY; VIRAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL SPECIFICITY; CHIMERA; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENE EXPRESSION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHAGE DISPLAY; VIROTHERAPY; VIRUS REPLICATION; VIRUS SURVIVAL; ADENOVIRIDAE; ANIMAL; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; CHO CELL LINE; CRICETULUS; GENETICS; HAMSTER; HEK293 CELL LINE; MALE; NUDE MOUSE; PEPTIDE LIBRARY; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; GLIOMA; HEK293 CELLS; HUMANS; MALE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PEPTIDE LIBRARY; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84941277707     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.008     Document Type: Article

References (32)

1. Young JS, Kim JW, Ahmed AU, et al. Therapeutic cell carriers: a potential road to cure glioma. Expert Rev Neurother 2014;14:651-660.
2. Kim JW, Glasgow JN, Nakayama M, et al. An adenovirus vector incorporating carbohydrate binding domains utilizes glycans for gene transfer. PLoS One 2013;8:e55533.
3. Nandi S, Lesniak MS. Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther 2009; 9:737-747.
4. Tobias A, Ahmed A, Moon KS, et al. The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry 2013;84:213-222.
5. Zheng S, Ulasov IV, Han Y, et al. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 2007;9:151-160.
6. Pointer KB, Clark PA, Zorniak M, et al. Glioblastoma cancer stem cells: biomarker and therapeutic advances. Neurochem Int 2014;71:1-7.
7. Sengupta S, Thaci B, Crawford AC, et al. Interleukin-13 receptor a2-targeted glioblastoma immunotherapy. Biomed Res Int 2014;2014:952128.
8. Wu C, Lo SL, Boulaire J, et al. A peptide-based carrier for intracellular delivery of proteins into malignant glial cells in vitro. J Control Release 2008;130:140-145.
9. Newton J, Deutscher SL. Phage peptide display. Handb Exp Pharmacol 2008;145-163.
10. Nixon AE, Sexton DJ, Ladner RC. Drugs derived from phage display: from candidate identification to clinical practice. MAbs 2014;6:73-85.
11. Curiel DT. Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci 1999;886:158-171.
12. Krasnykh V, Belousova N, Korokhov N, et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001;75:4176-4183.
13. Alberti MO, Roth JC, Ismail M, et al. Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation. PLoS One 2012;7:e37812.
14. Belousova N, Korokhov N, Krendelshchikova V, et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol 2003;77: 11367-11377.
15. Hedley SJ, Auf der Maur A, Hohn S, et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther 2006;13:88-94.
16. Ulasov IV, Rivera AA, Sonabend AM, et al. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther 2007;6: 679-685.
17. Hardcastle J, Kurozumi K, Chiocca EA, et al. Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 2007;7:181-189.
18. Ahmed AU, Thaci B, Tobias AL, et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst 2013;105:968-977.
19. Maizel JV, Jr., White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968;36:115-125.
20. Jung CS, Unterberg AW, Hartmann C. Diagnostic markers for glioblastoma. Histol Histopathol 2011; 26:1327-1341.
21. Liang S, Shen G, Liu Q, et al. Isoform-specific expression and characterization of 14-3-3 proteins in human glioma tissues discovered by stable isotope labeling with amino acids in cell culturebased proteomic analysis. Proteomics Clin Appl 2009;3:743-753.
22. Wang C, Ning L, Wang H, et al. A peptidemediated targeting gene delivery system for malignant glioma cells. Int J Nanomed 2013;8: 3631-3640.
23. Choi JW, Lee JS, Kim SW, et al. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 2012;64:720-729.
24. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011;8:12-28.
25. Khare R, Chen CY, Weaver EA, et al. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 2011;11: 241-258.
26. Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular and innate response, what's important? Hum Vaccin Immunother 2014;10:2875-2884.
27. Capasso C, Garofalo M, Hirvinen M, et al. The evolution of adenoviral vectors through genetic and chemical surface modifications. Viruses 2014;6: 832-855.
28. Tiesjema B, Hermsen HP, van Eijkeren JC, et al. Effect of administration route on the biodistribution and shedding of replication-deficient HAdV-5: a qualitative modelling approach. Curr Gene Ther 2010;10:107-127.
29. Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 2013;13:421-433.
30. Choi IK, Yun CO. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther 2013;20:70-76.
31. de Gruijl TD, van de Ven R. Chapter six-adenovirus-based immunotherapy of cancer: promises to keep. Adv Cancer Res 2012;115:147-220.
32. Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014;20:5290-5301.